Onychomycosis Market Size, Share, Opportunities, And Trends By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Others), By Treatment (Oral, Topical, Others), By Distribution Channel (Institutional Sales, Retail Sales), And By Geography - Forecasts From 2023 To 2028

  • Published : Dec 2023
  • Report Code : KSI061616125
  • Pages : 140

The onychomycosis market is projected to show steady growth during the forecast period.

Onychomycosis is a contagious disease that influences the nails of the fingers and toes. The onychomycosis market is growing at a rapid pace due to several factors, including the increasing prevalence of the infection. The market is expected to hold a significant value in the coming years, and several companies are investing in the development of new treatments and therapies for onychomycosis. The increasing awareness about the condition and the availability of advanced diagnostic and treatment options are expected to drive the growth of the onychomycosis market in the coming years.


The onychomycosis market deals with the diagnosis, treatment, and management of fungal infections that affect the nails of the fingers and toes. The onychomycosis treatment market is growing rapidly due to the rising prevalence of onychomycosis and the development of advanced diagnostic and treatment methods. The market can be segmented by type, diagnosis, and treatment. The market is expected to hold a significant value in the coming years, and several companies are investing in the development of new treatments and therapies for onychomycosis. However, the stringent regulatory requirements for the approval of new drugs and therapies may negatively impact the growth of the market.


  • Increasing Prevalence: The rising pervasiveness of onychomycosis is one of the essential drivers of the market. The condition is normal in both created and non-industrial nations, and the rising occurrence of the disease is driving the interest in cutting-edge analytics and treatment choices.
  • Technological Advancements: The improvement of cutting-edge demonstrative and treatment choices is driving the development of the onychomycosis market. The accessibility of innovations, like laser treatment and photodynamic treatment, is working on the adequacy of treatment and diminishing the time expected for treatment.
  • Awareness and Education: The rising mindfulness about onychomycosis and its side effects are driving the interest in demonstrative and treatment choices. The accessibility of instructive assets and mindfulness crusades is assisting with expanding mindfulness about the condition and diminishing the disgrace related to it.
  • Aging Population: The maturing populace is more defenseless to onychomycosis, and the rising number of old individuals is driving the development of the market. The predominance of onychomycosis in old individuals is confounded by illnesses, for example, diabetes and fringe vascular sickness, which increment the gamble of contamination.
  • Psychosocial and Emotional Effects: The psychosocial and profound impacts coming about because of onychomycosis are far-reaching and may fundamentally affect personal satisfaction. The effect of the condition on personal satisfaction is driving the interest in compelling treatment choices that can further develop the physical and close-to-home prosperity of patients.

Products offered by key companies:

  • Almirall offers a range of treatments for onychomycosis, including P-3058 (10% terbinafine nail solution). The solution is effective in clinical trials and is expected to be a key product for the company in the coming years.
  • Onycho Pharma is developing AMYCOT® a profoundly effectual normally inferred item to treat Onychomycosis (nail parasite). Created utilizing a licensed bioactive concentrate detailing to outfit the counter parasitic properties from the cyanobacteria strain, Arthrospiro Maxima.
  • Hexima is developing a new class of antifungal peptides that have broad-spectrum activity against fungal species. The peptides are designed to be safe and effective and have the potential to be a significant advance in the treatment of onychomycosis.

Prominent growth in the white superficial onychomycosis segment within the Onychomycosis Market:

 White superficial onychomycosis is a subtype of onychomycosis that is characterized by white chalky deposits on the surface of the affected nail plate. This subtype is caused by direct invasion of the surface of the nail plate by the fungus, and it can be easily scraped away with a curette or rotary burr. The white superficial onychomycosis segment is witnessing rapid growth due to the increasing incidence of immunocompromised conditions and the rising awareness and diagnosis of fungal nail infections. The increasing prevalence of onychomycosis and the availability of advanced diagnostic and treatment options are expected to drive the growth of the onychomycosis market in the coming years. The most common clinical subtype of onychomycosis is distal lateral subungual onychomycosis, which presents as partial distal onycholysis with subungual hyperkeratosis or crumbling.

The North American region is expected to hold a significant share of the Onychomycosis market :

The North American region is expected to hold a significant share of the onychomycosis market due to high drug costs, a rising geriatric population, and an increasing incidence of fungal nail infections. The region has also seen a growing awareness of the vast potential of onychomycosis drugs, which is fueling the market's expansion. Additionally, the rising awareness and diagnosis of fungal nail infections in North America are contributing to the market growth.

Key developments:

  • In March 2021, HUYABIO International as a team with its joint endeavor Tianjin Establishment of Drug Exploration submitted an NDA for Jublia, efinaconazole for the treatment of onychomycosis.
  • In September 2021, Sanofi announced the acquisition of Kadmon Holdings, a company that is developing new treatments for onychomycosis. This acquisition will give Sanofi access to Kadmon's pipeline of antifungals, Terbinafine, a drug in Phase III clinical trials for onychomycosis, is among the most promising new treatments for this condition.


  • By Type
    • Distal Subungual Onychomycosis
    • White Superficial Onychomycosis
    • Proximal Subungual Onychomycosis
    • Others
  • By Treatment
    • Oral
    • Topical
    • Others
  • By Distribution Channel
    • Institutional Sales
    • Retail Sales
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Research Process


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Distal Subungual Onychomycosis

5.3. White Superficial Onychomycosis

5.4. Proximal Subungual Onychomycosis

5.5. Others


6.1. Introduction

6.2. Oral 

6.3. Topical

6.4. Others


7.1. Introduction

7.2. Institutional Sales

7.3. Retail Sales


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations


10.1. Almirall

10.2. Onycho Pharma

10.3. Blue Cross NC

10.4. Hexima

10.5. Hallux Inc

10.6. Bausch Health

10.7. Avalon Healthcare Solutions

10.8. Canesten UK

10.9. Julbliarx

10.10. Ferozsons Laboratories Limited


Onycho Pharma

Blue Cross NC


Hallux Inc

Bausch Health

Avalon Healthcare Solutions

Canesten UK


Ferozsons Laboratories Limited